1. Home
  2. BFS vs SPRY Comparison

BFS vs SPRY Comparison

Compare BFS & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BFS

Saul Centers Inc.

HOLD

Current Price

$33.67

Market Cap

809.1M

Sector

Real Estate

ML Signal

HOLD

Logo ARS Pharmaceuticals Inc.

SPRY

ARS Pharmaceuticals Inc.

HOLD

Current Price

$8.27

Market Cap

833.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BFS
SPRY
Founded
1993
2015
Country
United States
United States
Employees
98
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
809.1M
833.1M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
BFS
SPRY
Price
$33.67
$8.27
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$44.00
$40.00
AVG Volume (30 Days)
38.0K
1.5M
Earning Date
05-07-2026
05-13-2026
Dividend Yield
6.99%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$84,278,000.00
Revenue This Year
$6.07
$90.76
Revenue Next Year
$7.05
$81.70
P/E Ratio
$30.48
N/A
Revenue Growth
N/A
N/A
52 Week Low
$29.16
$6.66
52 Week High
$35.45
$18.63

Technical Indicators

Market Signals
Indicator
BFS
SPRY
Relative Strength Index (RSI) 58.07 46.35
Support Level $32.42 $8.05
Resistance Level $35.32 $8.70
Average True Range (ATR) 0.70 0.54
MACD 0.14 0.07
Stochastic Oscillator 78.43 68.46

Price Performance

Historical Comparison
BFS
SPRY

About BFS Saul Centers Inc.

Saul Centers Inc is a self-managed real estate investment trust which invests in, operates and develops retail and commercial properties. The company's portfolio includes community and neighbourhood shopping centres, office properties, and mixed-use properties. Properties are located in the Washington, D.C. and Batlimore metropolitan areas. Saul Centers operates through two business segments: Shopping Centers segment, which contribute the maximum portion of total revenue; and mixed-use properties.Mixed-Use Properties segment include office, retail and multi-family residential use.

About SPRY ARS Pharmaceuticals Inc.

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.

Share on Social Networks: